Editas Medicine (NASDAQ:EDIT) EVP Linda Burkly Sells 7,814 Shares of Company Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) EVP Linda Burkly sold 7,814 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $2.42, for a total value of $18,909.88. Following the sale, the executive vice president owned 70,379 shares of the company’s stock, valued at approximately $170,317.18. The trade was a 9.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Linda Burkly also recently made the following trade(s):

  • On Thursday, September 3rd, Linda Burkly sold 709 shares of Editas Medicine stock. The stock was sold at an average price of $3.04, for a total value of $2,155.36.

Editas Medicine Stock Up 1.4%

Shares of EDIT stock traded up $0.03 during trading hours on Friday, reaching $2.17. 2,785,410 shares of the company’s stock were exchanged, compared to its average volume of 2,235,164. Editas Medicine, Inc. has a fifty-two week low of $1.66 and a fifty-two week high of $3.94. The stock has a market capitalization of $334.92 million, a P/E ratio of -3.50 and a beta of 2.08. The business has a fifty day moving average price of $2.63 and a 200-day moving average price of $2.69.

Editas Medicine (NASDAQ:EDIT – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Editas Medicine had a negative return on equity of 130.43% and a negative net margin of 144.95%. The company had revenue of $10.37 million during the quarter, compared to analysts’ expectations of $4.46 million. As a group, research analysts expect that Editas Medicine, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on EDIT. Wall Street Zen raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Editas Medicine in a report on Wednesday, November 4th. Guggenheim raised Editas Medicine from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Wednesday, September 23rd. Wells Fargo & Company upgraded shares of Editas Medicine from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $4.00 to $6.00 in a research report on Thursday, October 8th. Finally, Ladenburg Thalmann & Co. Inc. started coverage on shares of Editas Medicine in a report on Tuesday, August 18th. They set a “buy” rating and a $6.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Editas Medicine has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Get Our Latest Stock Report on Editas Medicine

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Editas Medicine in the 2nd quarter valued at $34,312,000. ADAR1 Capital Management LLC acquired a new position in shares of Editas Medicine during the second quarter valued at $28,800,000. State Street Corp lifted its stake in shares of Editas Medicine by 60.6% during the third quarter. State Street Corp now owns 7,038,580 shares of the company’s stock valued at $18,089,000 after acquiring an additional 2,654,974 shares during the period. Renaissance Technologies LLC boosted its holdings in Editas Medicine by 30.7% in the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company’s stock valued at $9,811,000 after acquiring an additional 932,382 shares during the last quarter. Finally, Opaleye Management Inc. boosted its holdings in Editas Medicine by 100.4% in the second quarter. Opaleye Management Inc. now owns 3,861,930 shares of the company’s stock valued at $12,513,000 after acquiring an additional 1,934,933 shares during the last quarter. Institutional investors and hedge funds own 71.90% of the company’s stock.

About Editas Medicine

(Get Free Report)

Editas Medicine, Inc. is a biotechnology company developing genome-editing medicines for people with serious diseases. Its research uses CRISPR-based technologies, including CRISPR-Cas9 and Cas12a, to make targeted changes to DNA. Founded in 2013 and based in Cambridge, Massachusetts, the company conducts research and clinical development of potential treatments for genetic disorders. Its work has included approaches designed to edit genes in a patient’s cells, either outside the body or directly within the body.

Featured Articles

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.